Clinical Trial: A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07181837) titled 'A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome' on Sept. 06.

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Angelman Syndrome

Intervention: GENETIC: MVX-220

AAVhu68 viral vector

Recruitment Status: NOT_YET_RECRUITING

Sponsor: MavriX Bio, LLC

Published by HT Digital Content Services with permission from Health Daily Digest....